Qualigen therapeutics provides update on developments at nanosynex; significant progress reported on infectious disease diagnostic platform

Carlsbad, calif., jan. 05, 2023 (globe newswire) -- qualigen therapeutics, inc. (“qualigen” or “the company,” nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today shares an update on its majority-owned subsidiary, nanosynex ltd. (“nanosynex”), the progress made during 2022, and objectives for 2023 concerning the commercialization plans for its innovative rapid antimicrobial susceptibility test (ast).
QLGN Ratings Summary
QLGN Quant Ranking